Board of Directors

Marianne Dicander Alexandersson

Marianne Dicander Alexandersson

Chair of the Board since 2021. Chairperson of the Nomination and Remuneration Committee. Member of the Risk and Audit Committee.

Born 1959.

Education: MSc. Chemical engineering, Chalmers University of Technology, Gothenburg, Sweden complemented with business studies. 

Background: Swedish national with a broad business and leadership experience. Many years of experience in the life science industry and from board work, including as CEO of Kronans Droghandel, Global Health Partner and the Sixth AP Fund, deputy CEO of Apoteket AB, and positions within quality and market development at Pharmacia, Imperial Chemical Industries and Volvo. 

Other current positions: Chairman of the Board of Saminvest AB, Sahlgrenska Science Park AB and The Royal Swedish Academy of Engineering Sciences (IVA Väst). Board member of Linc AB and Promore Pharma AB and Oblique AB. Member of the Advisory Council of the Dental and Pharmaceutical Agency, TLV. 

Prior positions (past five years): Board member of Xperentia AB, AdderaCare AB, Enzymatica AB (publ), Camurus AB, Praktikertjänst Aktiebolag and Recipharm AB (publ). 

Holdings in the Company (including related parties): 54,399 shares and no share options. 
Independent in relation to the Company and its management and the Company’s major shareholders.

Urs Christen

Urs Christen

Member of the board since 2020.

Born 1953.

Education: Laboratory chemist. 

Background: A Swiss national and is the founder, owner and CEO of the medical trading company Fumedica, which focuses on Interventional Cardiology, Structural Heart, Heart Surgery & General Surgery and has activities in Germany and Switzerland. Extensive experience as Chairman and as shareholder of various international companies in the above-mentioned fields such as Jotec GmbH (acquired by Cryolife in 2018) and New Valve Technology (acquired by Biosensors/Bluesail in 2020).

Other current positions: Chairman and CEO of Fumedica Switzerland & Germany. Chairman and CEO of Medira AG, Muri. Chairman Valvetronic Technologies SA, Charbonnières. Member of the Board and Vice President of Hotel Muri AG, Muri. Member of the Board of Muri Kultur.

Prior positions (past five years): Chairman of Jotec AB, Chairman and CEO of NVT AG.

Holdings in the Company (included related parties): 2,903,760 shares via Fumedica AG. No share options in the Company.
Dependent in relation to the Company and its management, but independent in relation to the Company’s major shareholders.

Mette-Marie Harild

Mette-Marie Sonne Harild

Member of the board since 2021. Member of the Nomination Committee and Remuneration Committee.

Born 1958.

Education: Governance education, Copenhagen Business School, Denmark and an Executive Master of Business and Economics in Change Management, Aarhus School of Business and Aarhus University, Denmark. Executive education (advanced leader), Wharton School of the University of Pennsylvania, U.S. Medif/Mefa-examination and educated Dentist from Copenhagen Dentist School, Denmark. Furthermore, several courses in Marketing and Sales Management. 

Background: A Danish national. Experience from pharma/medical industry for more than thirty years, among others as Regional Vice President ABGI & Nordic of Medtronic A/S. Chairman of AmCham Healthcare Committee and a board member in the Danish Chamber of Commerce, including chairman of the Life Science Board. Furthermore, board member of KEA (Københavns Erhvervsakademi) Advisory board and the Danish Business Development Board under the Ministry of Commerce. 

Other current positions: Board member of Neurescue Aps and Qlife Holding AB.

Prior positions (past five years): Chairman of AmCham Healthcare Committee and a board member of the Danish Chamber of Commerce as well as chairman of the Life Science Board for the Danish Chamber of Commerce. Furthermore, member of the Danish Business Development Board under the Ministry of Commerce (Dansk Erhvervsfremmebestyrelse). Regional Vice President ABGI & Nordic Medtronic A/S. 

Holdings in the Company (including related parties): 8,163 shares and no share options in the Company. 
Independent in relation to the Company and its management and the Company’s major shareholders.

Helena Levander

Helena Levander

Member of the Board since 2021. Chairperson of the Risk and Audit Committee.

Born 1957.

Education: Masters in Finance and Economics, Stockholm School of Economics, Sweden. 

Background: A Swedish national with 20 years of experience from the banking and finance sectors as well as from corporate governance and board work in Norway and Sweden. Previous roles include among others Senior Fund Manager at SEB, Nordea Bank and Odin Funds, and as CEO of NeoNet Securities AB and COO at NeoNet AB, an electronic equity trading platform. 

Other current positions: Chairman of the Board of Lannebo Fonder AB, Factoringgruppen AB, CAROLINE SVEDBOM AB and Ativo Finans AB. Board member of Stendörren Fastigheter AB (publ), Rejlers AB (publ), Concordia Maritime AB (publ) and Pensare Grande AB. Deputy board member of Spalten Vin & Gastronomi AB. 

Prior positions (past five years): Chairman of Medivir Aktiebolag and board member of Recipharm AB (publ), NeuroVive Pharmaceutical AB, Nordic Investor Services AB and Stampen AB. 

Holdings in the Company (including related parties): 54,399 shares and no share options.
Independent in relation to the Company and its management and the Company’s major shareholders.

Michel E. Lussier

Michel E. Lussier

Member of the board since 2021.

Born 1956.

Education: Master of Science, Biomedical Engineering, University of Montreal, Canada and a Master of Business Administration from INSEAD Business School. 

Background: A Canadian national and a seasoned Med-tech and Cell Therapy serial entrepreneur with solid expertise in the field of Interventional Cardiology, Congestive Heart Failure Management and Digital Health both in North America and in Europe. Currently chairman/cofounder of Celyad SA, a public clinical stage company initially in the field of cell therapy for Congestive Heart Failure and currently Cancer (CAR-T). Previous experience from Medtronic Inc and Volcano Corp, as Group President. Experience from several start-up companies. 

Other current positions: Chairman of Celyad Oncology SA (Euronext & Nasdaq: CYAD), iSTAR Medical SA and Gabi Smartcare SA. CEO of Medpole Ltd. Gerant on MEL Management. 

Prior positions (past five years): CEO of Metronom Health. 

Holdings in the Company (including related parties): 54,399 shares and no share options. 
Independent in relation to the Company and its management and the Company’s major shareholders.

Tor Peters

Tor Peters

Member of the board since 2009. Member of the Nomination Committee and the Remuneration Committee.

Born 1960.

Education: Bachelor of Science, University of Lund and an MBA from IMD in Switzerland. 

Background: A Swedish national with over 30 years of experience in senior positions at various med-tech companies, including BOC Ohmeda, Novo Nordisk, Scimed and Boston Scientific. Founder of several med-tech ventures and in 1996 co-founded JOMED, an innovative European interventional cardiology company, achieving the largest global med-tech IPO in 2000. Joined Occlutech in 2005 and held the position of Group CEO from 2009 to 2017 and Co-CEO from 2018 to 2020. 

Other current positions: Chairman of the Board, NOLabs AB, board member of SIC Invent Switzerland and CEO of Syntach AG, Switzerland. 

Prior positions (past five years): 

Holdings in the Company (including related parties): 26,209,433 shares and 57,480 shares options. 

Holdings as per September 15th, 2021.